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Abstract
To date, malignant pheochromocytomas and paragangliomas (PHEOs/PGLs) cannot be effectively cured and thus novel
treatment strategies are urgently needed. Lovastatin has been shown to effectively induce apoptosis in mouse PHEO cells
(MPC) and the more aggressive mouse tumor tissue-derived cells (MTT), which was accompanied by decreased
phosphorylation of mitogen-activated kinase (MAPK) pathway players. The MAPK pathway plays a role in numerous
aggressive tumors and has been associated with a subgroup of PHEOs/PGLs, including K-RAS-, RET-, and NF1-mutated
tumors. Our aim was to establish whether MAPK signaling may also play a role in aggressive, succinate dehydrogenase
(SDH) B mutation-derived PHEOs/PGLs. Expression profiling and western blot analysis indicated that specific aspects of
MAPK-signaling are active in SDHB PHEOs/PGLs, suggesting that inhibition by statin treatment could be beneficial.
Moreover, we aimed to assess whether the anti-proliferative effect of lovastatin on MPC and MTT differed from that exerted
by fluvastatin, simvastatin, atorvastatin, pravastatin, or rosuvastatin. Simvastatin and fluvastatin decreased cell proliferation
most effectively and the more aggressive MTT cells appeared more sensitive in this respect. Inhibition of MAPK1 and 3
phosphorylation following treatment with fluvastatin, simvastatin, and lovastatin was confirmed by western blot. Increased
levels of CASP-3 and PARP cleavage confirmed induction of apoptosis following the treatment. At a concentration low
enough not to affect cell proliferation, spontaneous migration of MPC and MTT was significantly inhibited within 24 hours
of treatment. In conclusion, lipophilic statins may present a promising therapeutic option for treatment of aggressive
human paragangliomas by inducing apoptosis and inhibiting tumor spread.
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Introduction
Recently, lovastatin has been suggested as promising potential
therapeutic option to treat RET, NF1, and TMEM127 mutation-
derived catecholamine producing adrenal and extra-adrenal
chromaffin cell tumors (pheochromocytomas (PHEOs) and
paragangliomas (PGLs), respectively) [1]. However, the risk for
metastatic disease in these tumors is relatively low and tumor
resection is thus almost always curative. In contrast, the risk for
malignant PHEOs/PGLs is particularly high in the case of
succinate dehydrogenase B (SDHB) gene mutations [2,3], and
novel treatment strategies are urgently needed for this condition.
A recent New England Journal of Medicine Article reported
decreased cancer-related mortality in patients who were pre-
scribed statins previous to diagnosis [4]. In agreement with this,
numerous in vitro and in vivo studies demonstrated anti-cancer
effects of lovastatin and other statins alone or as part of a
combined treatment regimen for aggressive tumors (reviewed in
[5–7]). At higher concentrations than are required for reduction of
cholesterol levels, statins have been shown to inhibit the
mevalonate pathway severely enough to inhibit the synthesis of
isoprenoids, which act as necessary membrane anchors for proper
function of certain proteins [8]. The anti-cancer effects of statins
have mainly been associated with inhibition of Ras-prenylation
(i.e. farnesylation or geranylgeranylation), which among other
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effects, disrupts activation of downstream players in the MAPK
pathway [9,10]. Over-activation of the mevalonate pathway,
including MAPK-signaling has been shown to be sufficient for cell
transformation [11]. Excessive MAPK signaling supports apopto-
sis inhibition, proliferation, and migration and is a key character-
istic of many cancer types (summarized in [12,13]). In case of
PHEOs/PGLs, elevated MAPK pathway activity is apparent in H-
RAS, K-RAS, TMEM127, RET, NF1, and possibly MAX mutation-
related tumors [14–22].
To our knowledge, currently no evidence for increased MAPK
signaling in SDHB-derived PGLs has been presented. In cells from
patients with Cowden-like syndrome and SDHB or D gene
variants, however, increased levels of MAPK 1 and 3 phosphor-
ylation have been observed [23]. In the presence of an active
MAPK pathway, statins may provide a promising treatment or co-
treatment option for currently fatal malignant PGLs.
The extent of the anti-cancer effects has been shown to vary
depending on model and type of statin used [24–30]. Thus, we
evaluated which of the seven currently available statins may be
most effective for PHEO/PGL treatment.
Materials and Methods
Fluvastatin, pravastatin, lovastatin, and simvastatin were all
obtained from Cayman Chemicals (Ann Arbor, MI); atorvastatin
and rosuvastatin were obtained from Enzo Life Sciences, Inc.
(Farmingdale, NY).
Cell culture
Mouse tumor tissue-derived (MTT) cells have been recently
developed in our lab [31]. All animal studies necessary for
development and characterization of MTT cells were conducted
in accordance with the principles and procedures outlined in the
National Institute of Health Guide for the Care and Use of
Animals, and approved by the Eunice Kennedy Shriver National
Institute of Child Health and Human Development Animal Care
and Use Committee (Protocol number ASP# 06-028). MTT cells
are property of the NIH. Mouse pheochromocytoma cells (MPC
4/30PRR) were a generous gift from Dr. Tischler, TUFTS,
Boston. Cells were maintained in DMEM (Gibco, Life Technol-
ogies, Grand Island, NY), supplemented with 10% heat-inactivat-
ed horse serum (Hyclone Logan, UT), 5% fetal bovine serum
(Gibco), HEPES (Gibco), and penicillin (10,000 units/ml)/strep-
tomycin (100,000 mg/ml) (Gibco) in a humidified atmosphere
containing 5% CO2 at 37uC. Medium was changed every other
day and cells were passaged when 80-90% confluence was
reached. All statins were compared to the appropriate concentra-
tion of vehicle (DMSO). When statins were combined to evaluate
potential additive effects, 25 mM of 2 different statins were
compared to 50 mM of each of the individual statins.
Proliferation assays
Cells were seeded into collagen coated 96-well plates (BD
Biosciences, San Jose, CA) at 10,000 cells per well, and allowed to
attach for 24 h. Then media was exchanged with concentrations
of 6.25, 12.5, 25, and 50 mM of the different statins, dissolved in
supplemented media. After 0, 24, 48, and 72 h of treatment, cell
proliferation was assessed with the Cell Proliferation Kit II (XTT)
(Roche applied science; Indianapolis, IN) according to the product
manual. After four hours of incubation, the plates were measured
at 490 nm with 650 nm reference wavelength in a microplate
reader (Victor3 1420 multilabel counter, Perkin Elmer, Waltham,
MA). All experiments were performed in quadruplicate and
repeated at least twice.
Spontaneous cell migration assays
Cells were seeded at 60,000 cells per well for spontaneous
migration assessment in an xCELLigence DP device (Roche
Diagnostics, Mannheim, Germany) as previously reported [32].
The spontaneous migration was recorded for 24 hours in the
presence of 5 mM fluvastatin, lovastatin, and simvastatin alone, or
in combination with 100 mM trans, trans farnesol (Sigma-Aldrich
Co., St. Louis, MO, USA).
MAPK pathway gene-enrichment in SDHB PGLs
Expression data was extracted from previously presented
microarray data on 45 samples of pseudohypoxic PHEOs/PGLs,
including 18 SDHB, 8 SDHD head and neck (HN), 6 SDHD
abdominal and thoracic (AT), and 13 VHL samples compared to
normal adrenal medulla [33]. As reported, prediction analysis of
microarray identified 6937 genes as characteristic for one of the
different subgroups of pseudohypoxic PHEOs/PGLs. These were
mapped against a list of 254 MAPK pathway genes (Kyoto
Encyclopedia of Genes and Genome Pathway). Predominant over-
expression in SDHB samples compared to normal medulla was
confirmed by ANOVA and intervals were based on the
Studentized range statistic, Tukey’s ‘‘Honest Significant Differ-
ence’’ method.
Ethics Statement
Tissue collection was approved by the institutional review board
of the Eunice Kennedy Shriver National Institutes of Child Health and
Human Development. Written informed consent was obtained
from each patient.
Human tumor tissue
PHEO/PGL tissue was immediately frozen upon resection.
Patient and tumor information for each sample are presented in
Table 1. Frozen samples were homogenized on ice in Tissue
Protein Extraction Reagent (Thermo Fisher Scientific Inc.,
Lafayette, CO, USA) with 0.1% phosphatase inhibitor (Cell
Signaling Technology Inc., Danvers, MA, USA) and one protease
inhibitor Complete Mini tablet per 10 ml solution (Roche Applied
Science, Indianapolis, IN, USA). Homogenates were centrifuged
at 10,0006g for 5 minutes at 4uC. The supernatant was used as
protein extract.
Cell harvesting
Cells were seeded in collagen coated plates [34] at
600,000 cells/ml and allowed to attach for a minimum of 18 h
before media was changed to 25 mM statin solutions or DMSO
control. Treatment solutions were renewed after 24 h. After 48 h
of treatment, cells were collected with a rubber policeman and
washed 3 times in ice cold PBS by centrifugation at 5006g. Cells
were collected at 15006g, dissolved in 0.1% cholamidopropyldi-
methylammoniopropanesulfate, containing one protease inhibitor
Complete Mini tablet per 7 ml solution (Roche Applied Science)
and 0.5% Phosphatase Inhibitor Cocktail 2 (Sigma-Aldrich Co.).
Samples were sonicated for 2 min on ice and subsequently
centrifuged at 10,0006g for 10 min, 4uC. The supernatant was
used as protein extract.
Western blot
To estimate protein concentrations the Quant-iT Protein Assay
Kit (Invitrogen, Life Technologies Corporation) was used. Equal
protein amounts of tumor extracts in PAGE gel LDS sample
buffer (Thermo Fisher Scientific) or cell extracts in La¨mmli buffer
were loaded onto 4–20% Criterion TGX precast gels (Bio-Rad
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Laboratories, Hercules, CA, USA) or hand cast 12% gels,
separated by sodium-dodecylsulfate polyacrylamide gel electro-
phoresis, and transferred to PVDF membranes (Immobilon-P,
EMD Millipore Corporation, Billerica, MA, USA). Membranes
were blocked in 5% non-fat dry milk in phosphate buffered saline
(pH 7.4) with 0.01–0.05% Tween 20 (Sigma-Aldrich Co.) for
1 hour. Antibodies were dissolved in 5% bovine serum albumin or
5% non-fat dry milk in tris-buffered saline (pH 7.6) with 0.01–
0.05% Tween 20. Membranes were incubated with primary
antibodies overnight at 4 uC or for 1 h at room temperature.
Table 1. Patient information.
Sample ID Gender Age at resection Location Mutation Characteristic
B1 M 38.2 E SDHB PM
B2 F 11.4 E SDHB P
B3 M 53.1 E SDHB P
B4 M 44.2 E SDHB MM
B5 M 34.1 E SDHB MM
B6 F 42.3 E SDHB MM
D1 F 44.6 HN SDHD P
D2 M 39.6 HN SDHD P
D3 F 11.8 HN SDHD P
N1 M 17.0 A NF1 P
N2 M 26.6 A NF1 P
M1 unknown unknown A - N
M2 unknown unknown A - N
Abbreviations: A: adrenal, E: extra-adrenal, F: female, HN: head and neck, ID: identifier, M: male, MM: metastatic metastases, N: normal, P: primary non-metastatic, PM:
primary metastatic.
doi:10.1371/journal.pone.0097712.t001
Figure 1. MAPK pathway representation in SDHB-derived PHEOs/PGLs. A. Western blot of pMAPK1/3, total MAPK1/3, and GAPDH in human
PHEOs/PGLs. Patient and tumor information for each sample are presented in Table 1. Abbreviations: B) SDHB, D) SDHD, N) NF1, M) normal adrenal
medulla. B. Heatmap showing expression of 21 MAPK pathway genes in pseudohypoxic PHEOs/PGLs. Expression of these 21 genes was significantly
elevated in SDHB compared to normal medulla (p,0.002). Each sample was assigned a number. The corresponding sample identifier from the
original article [33] is given in Table S1. Patient information and link to deposited data are given in the original article.
doi:10.1371/journal.pone.0097712.g001
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Primary antibodies were rabbit anti-cleaved-caspase-3, rabbit anti-
p44/p42 MAPK, rabbit anti-phospho-p44/p42 MAPK, rabbit
anti-PARP, rabbit anti-GAPDH (Cell Signaling, Technology Inc.),
mouse anti-b-actin (Sigma-Aldrich). Secondary antibodies were
HRP-linked donkey anti-rabbit (GE Healthcare, Pittsburgh, PA,
USA), goat anti-rabbit, and goat anti-mouse (both DAKO North
America, Inc., Carpinteria, CA). Membranes were incubated in
Super Signal West Pico Chemiluminescent Substrate (Thermo
Fisher Scientific) and exposed to High Performance Chemilumi-
nescence film (GE Healthcare) or incubated in Amersham ECL
Prime Western Blotting Detection Reagent (GE Healthcare) and
visualized in a ChemiDoc system (Bio-Rad Laboratories). Mem-
branes were stripped with Restore PLUS Western Blot Stripping
Buffer (Thermo Fisher Scientific) before re-blocking and incuba-
tion with another secondary antibody.
Statistical analysis
A two-step approach was used to assess the anti-proliferative
efficacy of each drug to decrease cell viability. In the first step,
each of the 6 drugs was compared separately to vehicle for each
level of treatment duration, dose, and cell type. The data used for
these analyses were the (replicated) ratios of the drug well values
divided by the mean of the associated set of DMSO control values.
These ratios, from 2 to 4 independent experiments, were analyzed
using a two-way fixed-effects ANOVA. The resulting p-values
were Bonferroni-corrected by multiplying them by 24, the number
of configurations of duration, dose, and cell type for a given drug.
Next, drugs that overall significantly decreased proliferation were
selected and the most effective durations and doses for each drug
for each cell type were assessed: by an initial ANOVA, followed by
ranking on the basis of post-ANOVA means, followed by Student-
Newman-Keuls (SNK) post hoc tests to determine which means
differed significantly. The overall performances of the 3 best
performing drugs were compared using a 4-way ANOVA (factors:
drug, duration, dose, and cell type); again SNK post hoc tests were
done to determine which drugs were overall significantly different.
The effect of combined statins compared to each individual
statin was evaluated in an analogous manner. Data are presented
as the mean and standard error (based on the ANOVA and the
delta-method) of at least two independent experiments. Statistical
calculations were performed in Stata (Release 12, StataCorp.,
College Station, Texas, USA).
Results
Evidence for MAPK-signaling in SDHB PHEOs/PGLs
As previously demonstrated, lovastatin exerted a strong anti-
proliferative effect on MPC and MTT cells, which was associated
with decreased phospho-MAPK 1 and 3 (pMAPK1/3) levels [1].
To evaluate whether statin treatment may be of benefit to patients
with metastatic PGLs, we assessed whether pMAPK1/3 was
present in the aggressive SDHB-derived PGLs and other
hereditary PHEOs/PGLs (Fig. 1A). Patient and tumor informa-
tion for each sample are presented in Table 1. Among the human
PHEOs/PGLs the pMAPK1/3 levels were highly variable.
Although the average pMAPK1/3 levels were comparably low
in SDHB tumors relative to other tested samples, phosphorylation
was evident in 4 out of six SDHB samples. No difference between
primary SDHB PGLs and SDHB-metastases was evident.
In addition, we evaluated the mRNA expression profile of
MAPK pathway genes in pseudohypoxic PHEOs/PGLs. Mapping
of 254 MAPK pathway genes to 6937 previously identified genes
of interest [33] revealed a match of 85 genes. Hierarchical
clustering of those 85 genes revealed two gene clusters, one of
which contained 21 genes that appeared to be more highly
expressed in SDHB and SDHD-AT PHEOs/PGLs compared to
normal adrenal medulla and SDHD-HN and VHL PHEOs/PGLs
(Fig. 1B). A closer look at these 21 genes revealed overall increased
expression in the SDHB samples compared to normal adrenal
medulla (p,0.002) (Fig. 1B) and an ANOVA of the individual
genes with post-hoc evaluation confirmed significantly higher
expression of MAPK12, CACNB3, CACNG7, MAP4K2,
MAP3K9, and MAPK6 in SDHB PHEOs/PGLs than normal
adrenal medulla (p#0.02). Thus, certain aspects of MAPK
signaling appear to be activated in the most aggressive SDHB-
derived PHEOs/PGLs, so targeting this pathway may be a
promising new treatment approach.
Comparison of in vitro efficacies of different statins
To determine the efficiency of different statins on PHEOs/
PGLs, we used two mouse models; MTT and MPC cell lines. No
evidence for succinate dehydrogenase dysfunction or subunit
mutation is expected in MPC or MTT cells, however currently no
better in-vitro model exists to study the effect of new therapeutic
options for PHEOs/PGLs. Relative cell viability decreased with
increasing treatment duration and concentration of the different
statins for MPC and MTT. Duration of three days of treatment
with the highest concentration of 50 mM was most effective for all
statins (Fig. 2) and showed a significantly higher effect compared to
the same dose and statin on the second day of treatment (SNK p#
0.029 for all statins except pravastatin, which was ineffective).
The occurrence of significantly decreased relative viability
compared to vehicle increased with dose and treatment durations
and these effects were more pronounced for MTT than MPC,
Figure 2. Effect of 6.25–50 mM statin treatment for 3 days on
MPC and MTT proliferation. Percent significant results over all
statins for all treatment doses at the different treatment durations for
MPC (A) and MTT (B). The percentage of significant results was
increased in MTT compared to MPC after 48 and 72 h, suggesting that
MTT are more sensitive to statin treatment.
doi:10.1371/journal.pone.0097712.g002
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Figure 3. Relative proliferation of MPC and MTT under statin treatment. MPC (A–F) and MTT (G–K) were treated with & 6.25 mM, m
12.50 mM, . 25.00 mM, and X 50.00 mM of atorvastatin, fluvastatin, lovastatin, pravastatin, rosuvastatin, and simvastatin for 24, 48, and 72 hours.
doi:10.1371/journal.pone.0097712.g003
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indicating a higher susceptibility of the more aggressive cell type to
treatment with statins (Fig. 2).
The anti-proliferative effect of the six statins differed signifi-
cantly (p,0.0001). Lovastatin, simvastatin, and fluvastatin dem-
onstrated highest proliferation inhibition (Fig. 3). Direct compar-
ison of their anti-proliferative efficacies revealed higher potency of
simvastatin and fluvastatin compared to lovastatin (p = 0.033;
simvastatin vs. lovastatin SNK p=0.043, fluvastatin vs. lovastatin
SNK p=0.031).
In addition to establishing which statin is most effective in
inhibiting cell proliferation in MPC and MTT, we explored
whether combining two different statins might increase efficacy.
Interestingly, the four most effective combinations all included
simvastatin: simvastatin/lovastatin, simvastatin/fluvastatin, sim-
vastatin/atorvastatin, and simvastatin/rosuvastatin. However,
none of these combinations decreased relative viability more
effectively than the three most effective statins, fluvastatin,
simvastatin, and lovastatin alone (Fig. 4).
Western blot revealed that the three most effective statins all
inhibited MAPK phosphorylation at 48 h of treatment with
25 mM (Fig. 5A). In addition, fluvastatin, simvastatin, and
lovastatin increased cleavage product levels of CASP-3 and
PARP, indicating increased apoptosis (Fig. 5B).
Proliferation of neither MPC nor MTT was impacted by
6.25 mM of any tested statin after 24 or 48 h. However,
spontaneous cell migration of MPC and MTT was severely
inhibited by treatment with 5 mM of fluvastatin, simvastatin, and
lovastatin (Fig. 6). Migratory capacity was partly rescued by
addition of 100 mM trans, trans farnesol.
Discussion
To date, no curative treatment has been established for
metastatic PHEOs/PGLs. However, several new therapeutic
strategies have been recently tested in model organisms [35–38],
including lovastatin [1]. Previously, statins have been reported to
decrease proliferation, survival, cell cycle progression, and
migration in other cells including aggressive cancer models,
amongst others by MAPK pathway inhibition [10,25–
27,29,30,39–41]. However, currently evidence that statin treat-
ment will be potent in the most aggressive type of PHEOs/PGLs,
i.e. those with SDHB mutations [42], is lacking.
Our data indicate that MAPK1/3 phosphorylation is present in
some SDHB-PGLs, including metastases. In agreement a previous
study showed increased MAPK1/3 phosphorylation in immortal-
ized lymphoblastoids from patients with Cowden-like syndrome
and germline SDHB or SDHD gene variants or mutations [23]. In
addition, several MAPK pathway genes appeared to be more
highly expressed in SDHB-PGLs than in normal adrenal medulla.
The exact function and potential involvement of the identified
genes in SDHB-mutation mediated tumorigenesis remain to be
evaluated.
In conclusion at least a subset of patients with aggressive PGLs
which show MAPK1/3 phosphorylation may benefit from statin
treatment. Our data indicates that this patient group may not be
restricted to cluster 2 PGL patients. Determination of MAPK1/3
phosphorylation on a case by case basis in metastatic PGLs may be
useful for estimation of a potential benefit of statin treatment.
Figure 4. Combination of two different statins to evaluate
potential additive effects on MPC or MTT. Relative viability of MPC
(A) and MTT (B) at the indicated doses and durations for the most
effective combined treatments including simvastatin relative to
simvastatin alone.
doi:10.1371/journal.pone.0097712.g004
Figure 5. Expression of selected proteins in MPC and MTT after
treatment with fluvastatin, simvastatin, or lovastatin. A. Western
blot showing decreased levels of pMAPK1/3 in treated vs. untreated
MPC and MTT relative to total MAPK1/3 and GAPDH. B. Western blot
showing decreased levels of intact PARP (top bands) and increased
levels of cleaved PARP (lower bands) in treated vs. untreated MPC and
MTT. In accordance, cleaved CASP-3 was elevated in treated cells,
indicating apoptosis. Cells were treated with 25 mM of the indicated
statin for 48 hours.
doi:10.1371/journal.pone.0097712.g005
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In a previously published microarray based study comparing
PHEOs/PGLs with different genetic backgrounds, SDHx-derived
tumors showed decreased MAPK pathway gene expression
relative to RET, NF1, TMEM127, and sporadic PHEOs/PGLs
[21]. The discrepancy between this result and our data may be due
to the fact that, relative to RET, NF1, TMEM127, and certain
sporadic PHEOs/PGLs, the up-regulation of MAPK signaling
genes may be marginal in SDHB PHEOs/PGLs, and thus not
detectable in the absence of normal control tissue. Our microarray
data revealed opposing expression patterns in SDHB and SDHD-
HN PGLs with respect to MAPK signaling genes; thus grouping
those samples may obscure the over-expression of MAPK-related
genes in SDHB PHEOs/PGLs compared to other PHEOs/PGLs.
Here we present several MAPK signaling genes that are up-
regulated relative to normal adrenal medulla. Thus, we conclude
that statin treatment by itself or combined with other therapeutic
regimens may be of benefit in certain SDHB-derived PHEOs/
PGLs.
Currently, seven different statins are on the market that – in
addition to their cholesterol lowering characteristics – have been
shown to interfere with several cancer relevant pathways [43,44].
Their pharmacological actions and impact on gene expression
have been shown to differ [43,45,46] and thus, depending on the
cells to be treated, the most effective drug has to be determined.
Here we show that in case of MPC and MTT, the lipophilic statins
fluvastatin, simvastatin, and lovastatin considerably reduced cell
proliferation, with simvastatin and fluvastatin showing slightly
stronger effects. Pravastatin has been shown to be ineffective in
several cancer models [47,48], which may be due to its hydrophilic
characteristics and the lack of appropriate transporters on the
tumor cells. In other studies comparing the effects of several
statins, simvastatin or fluvastatin appeared more effective than
lovastatin [24,30]. For further studies, consideration may be given
Figure 6. Influence of statin treatment on spontaneous cell migration. MPC (A) and MTT (B) were plated in vehicle (Ctr), 5 mM fluvastatin
(Fluva), 5 mM simvastatin (Simva), 5 mM lovastatin (Lova) with or without 100 mM trans, trans farnesol (FOH) and spontaneous migration was recorded
for 24.
doi:10.1371/journal.pone.0097712.g006
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to the fact that the pharmacokinetic characteristics of fluvastatin
have been reported to be preferable to those of simvastatin and
lovastatin [45].
Interestingly, the more aggressive MTT cells appeared to be
more sensitive to statin treatment, which indicates that more
aggressive cells may be more receptive to the anti-proliferative
effects of statins. The difference in mechanism rendering MTT
more susceptible remains to be elucidated.
The maximum statin concentration reported in human blood
after oral administration (12.3 mM) [49] was in the range of our
third highest concentration (12.5 mM), which significantly de-
creased cell proliferation in MPC and MTT at 48 or 72 hours of
treatment with fluvastatin, lovastatin, and simvastatin. Holstein
et al. reported that up to 415 mg/m2 orally every six hours over
four days were well tolerated by patients with severe malignancies
[49]. However, blood statin levels did not increase in a linear
manner, and thus oral administration may not be the best option
to achieve high tissue concentrations. Optimal administration
techniques to achieve the targeted concentrations will have to be
determined. Negligible effects of statins on normal cells compared
to cancerous cells have been reported [24,50].
At non-toxic concentrations, achievable by oral administration,
statins have been reported to exhibit another anti-cancer effect,
the inhibition of cell migration and invasion [9,47,51]. For this
reason we tested the consequence of the effective statins,
lovastatin, simvastatin, and fluvastatin on spontaneous cell motility
of MPC and MTT at 5 mM. Our proliferation assays showed no
reduction in proliferation at 6.5 mM within 24 hours of treatment.
Lovastatin, fluvastatin, and simvastatin effectively inhibited
migration of MPC and MTT within 24 hours. The migration-
inhibition appeared to be at least partly dependent on farnesyl
depletion, since presence of trans, trans farnesol partly rescued
migratory capacity. However, even a relatively high concentration
of 100 mM trans, trans farnesol did not entirely reverse the anti-
migratory effect of the three statins. Thus, farnesylation-indepen-
dent effects of statins on MPC and MTT cannot be excluded. In a
previous study, geranylgeranyl pyrophosphate has been shown to
be more effective in reversing the effect of statins than
farnesylpyrophosphate [24]. In addition, non-mevalonate pathway
dependent statin effects on cancer cells have also been described
[43].
Since oral administration of statins does not yield concentrations
as high as used here to achieve the best anti-proliferative effects in
vitro, combined administration of other drugs appears to be a
promising strategy. The multikinase inhibitors sunitinib and
sorafenib also affect the MAPK pathway and have been shown
to be effective in progressive metastatic PGLs [52,53]. Sunitinib
treatment showed beneficial clinical effects in 8 out of 17 patients
with progressive metastatic PGLs. Interestingly, 6 of the respond-
ers carried SDHB-mutations. However, as most anti-neoplastic
drugs, the side effects of multikinase inhibitors can be severe and
nine of the 17 patients treated with sunitinib had to discontinue
treatment or decrease the dose eventually.
A synergistic effect of fluvastatin and sorafenib has been
presented for melanoma cells in vitro [54]. This holds the
potential of decreasing multikinase inhibitor concentrations, which
may relieve the severity of side effects while anti-tumor perfor-
mance is maintained. However, further studies are mandated to
establish whether combination of multikinase inhibitors with
statins may have additive effects in aggressive PGLs. As previously
reported, combined inhibition of PI3K/AKT and mTORC1/2
signaling has been suggested as promising therapeutic regimen for
certain PGLs [1].
In conclusion, statins may be of benefit alone or in combination
with other therapeutic regimens in patients with aggressive
PHEOs/PGLs which show MAPK pathway activity.
Supporting Information
Table S1 Sample numbers from Figure 1A with corre-
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